As for organ-unspecific fatal adverse events, substantial cases of sepsis and neutropenia were recorded.<h4>Conclusion</h4>This study firstly provided a comprehensive incidence and the spectrum of fatal adverse events associated with PD-L1 inhibitors, and identified three potential susceptible factors of that, yielding a capability for clinicians to distinguish high-risk populations from relatively low-risk ones, and facilitating to improve the safety of PD-L1 inhibitors broadly used in the clinical setting. This evidence concerns the gene CD274 and Sepsis.